Login to Your Account



Clinic Roundup


Thursday, February 14, 2013
• Dendreon Corp., of Bridgewater, N.J., reported findings from several ongoing or completed studies of Provenge (sipuleucel-T) in advanced prostate cancer ahead of the 2013 American Society of Clinical Oncology Genitourinary Cancers Symposium in Orlando, Fla.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription